Back to Journals » International Medical Case Reports Journal » Volume 15
Case report
Case Reports
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
The Role of Brentuximab Vedotin (BV) as Second-Line Treatment of Refractory Classical Hodgkin Lymphoma (cHL) in the Era of Pandemic COVID-19
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
5,179 | Dovepress* | 4,857+ | 244 | 5,101 | |
PubMed Central* | 322 | 53 | 375 | ||
Totals | 5,179 | 297 | 5,476 | ||
*Since 1 June 2022 |
Total mentioned | Delicious | Others | |||
---|---|---|---|---|---|
5 | 0 | 0 | 0 | 2 | 3 |
View citations on PubMed Central and Google Scholar